NewLink Genetics Corp. today announced that it has appointed Dr. Thomas Monath as chief scientific officer and chief operations officer of its wholly-owned subsidiary, BioProtection Systems Corp.  A world-renowned virologist and vaccinologist, Monath's main focus will be to provide oversight and direction of the development of the company's VSV-EBOV Ebola vaccine candidate licensed from the Public Health Agency of Canada. He has more than 25 years of experience as a senior biotechnology industry executive and has successfully developed and provided clinical trial oversight of multiple vaccines. He also has extensive experience and success working with the U.S. Food and Drug Administration. In September, Monath was second on the list of "50 Most Influential People in Vaccines" by VaccineNation, behind billionaire philanthropist Bill Gates.